---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-25-036830"
form_type: "8-K"
ticker: "ACHV"
cik: "0000949858"
company_name: "ACHIEVE LIFE SCIENCES, INC."
filed_at: "2025-03-11T23:59:59+00:00"
generated_at: "2026-05-25T00:36:52.412556+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Achieve Life Sciences reports Q4 net loss $12.4M; reiterates cytisinicline NDA by end of Q2 2025

## Summary
- Cash, cash equivalents and marketable securities $34.4M as of Dec 31, 2024.
- Net loss for Q4 2024 was $12.4M; full-year net loss $39.8M (pre-revenue).
- NDA submission for smoking cessation cytisinicline expected end of Q2 2025; ORCA-OL enrollment complete.
- Appointed Mark Oki as CFO, Dr. Kristen Slaoui and Nancy Phelan to Board.
- FDA agreed Phase 3 ORCA-V2 trial design for vaping cessation; plans to initiate in H1 2026.

## SEC filing metadata
- accession: 0000950170-25-036830
- form_type: 8-K
- ticker: ACHV
- cik: 0000949858
- company_name: ACHIEVE LIFE SCIENCES, INC.
- filed_at: 2025-03-11T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/949858/000095017025036830/0000950170-25-036830-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/949858/000095017025036830/achv-20250311.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-25-036830
- JSON: https://secwatch.observer/filing/0000950170-25-036830.json
- Plain text: https://secwatch.observer/filing/0000950170-25-036830.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.